Actinium Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ATNM | ATORX.ST | CLRB | HBP.TO | PYXS | SCLP.L | |
|---|---|---|---|---|---|---|
| Market cap | 44.33M | 38.54M | 11.63M | 70.27M | 198.30M | 116.66M |
| P/E (TTM) | 3.9 | — | — | — | — | — |
| Forward P/E | -2.7 | -0.1 | -0.6 | -8.4 | -1.5 | -370.6 |
| Price/book | 1.5 | 0.3 | 0.3 | 4.8 | 9.2 | -4.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +4.48% | −99.44% | −64.14% | −54.68% | −58.91% | −13.71% |
| Today | +0.71% | +0.93% | −6.11% | 0.00% | +1.22% | +1.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ATNM news ›Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across... - The three abstracts strengthen the clinical foundation for Iomab-ACT's…
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies,... NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE…
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
PR Newswire - Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes - ATN
aTyr Pharma publishes ATYR0101 data in Journal of Biological Chemistry
aTyr Pharma (ATYR) announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. ATYR0101 ... aTyr Pharma publishes ATYR0101 data in Journal of Biological Chemistry aTyr Pharma (ATYR)…
Radiopharmaceutical Design Shifts Focus from Peak Yield to Robustness
A position paper argues that radiochemical robustness, not just peak radiochemical yield, should be a co-equal design criterion in radiopharmaceutical development. Radiopharmaceutical Design Shifts Focus from Peak Yield to Robustness The…
Scandium-44 moves closer to the clinic with reproducible production and radiolabelling method
Researchers report an optimized scandium-44 production and separation method achieving radionuclidic purity above 99 percent and automated DOTATOC labelling with 85 percent yield, moving the PET radionuclide toward clinical use.
Actinium Brings ATNM-400's Next-Generation Radiotherapy Approach To EANM 2026
Actinium Pharmaceuticals, Inc. (ATNM), a biotechnology company developing targeted radiotherapies for cancer, announced that it will present clinical and preclinical data on its investigational drug candidate ATNM-400 at the 39th Annual…
Research-Industry Push to Advance Actinium-225 Cancer Therapies
Wollongong-based online news outlet covering Australia and beyond. If you have anything newsworthy - a story, video or picture to share with us, please email us. CRP participants during a session with industry representatives Developing…
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Published on 10/16/2026 at 08:31 am EDT In NSCLC, ATNM-400 demonstrated antitumor activity as monotherapy and enhanced activity in combination with KRAS or ALK inhibitors, including in resistant models. These findings extend earlier…
Actinium Pharmaceuticals, Inc. Unveils Atnm-400 Data At Eanm 2026 with First-In-Human Her3-Targeted Radiotherapy Approach Beyond Psma in Prostate Cancer
Actinium Pharmaceuticals, Inc. announced encouraging initial clinical results from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer . The findings,... announced encouraging initial clinical…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- stocktitan.net8
- prnewswire.com4
- gurufocus.com1
- markets.businessinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.